HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Psychiatry
FDA Approval
Prochlorperazine Labeling: Indicated for Severe Nausea/Vomiting and Schizophrenia
The FDA approved a new injection to treat severe nausea and schizophrenia when pills cannot be taken.
FDA labeling for prochlorperazine lists two approved indications: control of severe nausea and vomiting and treatment of schizophrenia. The …
A new FDA-approved injection now treats severe nausea and schizophrenia when patients cannot take pills by mouth.
FDA
Apr 15, 2026
Anesthesiology & Pain Medicine
RCT
Oliceridine PCA non-inferior to sufentanil for knee arthroplasty pain, with lower nausea and vomiting
Oliceridine shows similar pain relief to sufentanil after knee surgery with fewer side effects
A randomized controlled trial in 138 elderly patients undergoing knee arthroplasty found Oliceridine patient-controlled analgesia was non-in…
Oliceridine works as well as sufentanil for knee surgery pain but causes less nausea and vomiting in elderly patients.
Apr 6, 2026
Rheumatology
Meta-analysis
Meta-analysis finds nausea in 24% and abdominal pain in 20% of RA patients on methotrexate
How common is nausea and stomach pain for RA patients on methotrexate?
A systematic review and meta-analysis of 37 studies involving 19,986 adult RA patients on methotrexate found pooled prevalence rates of 24.3…
Nearly one in five rheumatoid arthritis patients taking methotrexate experience nausea or stomach pain, with about 8.5% stopping the drug du…
Apr 1, 2026